Tag Archives: mirvetuximab soravtansine

June, 2018

18 June
FDA Grants Fast Track Status to ImmunoGen’s Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead program, mirvetuximab soravtansine. The designation is for the treatment of patients with …
Share

5 February
ImmunoGen and Merck Partner for Ovarian Cancer Combination Therapy Study

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, and Merck, known as MSD outside the United States and Canada, announced today that they have entered into a clinical research collaboration for the assessment of ImmunoGen’s mirvetuximab soravtansine in combination with …
Share